Hanmi Pharm secures 10-year supply contract
한미약품
128940
Signal Score
Historical Avg Return (5d)
+0.15%
Data Coverage
100%n=723
Risk-adjusted indicator based on 723 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Contract Value: 52.74B KRW
- • % of Recent Revenue: 3.4%
- • Contract Duration: 10 years (2026-2036)
- • Milestone (License fee): 1.075M USD
- • Estimated 10-year Sales: 34.09M USD
AI Analysis Summary
Hanmi Pharm. Co., Ltd. signed a 10-year supply contract for three cardiovascular and respiratory treatments with Organon International GmbH, valued at 52.74B KRW. This represents 3.4% of the company's 2025 consolidated revenue of 1.55T KRW. The contract includes a 1.075M USD milestone fee and an estimated 34.09M USD in sales over 10 years, starting May 2026. The deal is positive, but subject to local regulatory approvals in the Philippines and Malaysia, and potential fluctuations due to inflation, exchange rates, and competition.
How This Event Is Evaluated
Strategic Contract Evaluation
Contract events are evaluated by measuring business scale, revenue relevance, counterparty quality, and execution visibility.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Contract size relative to company revenue
- Expected revenue impact
- Counterparty quality
- Contract duration and execution period
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.